A noncompetitive N-methyl-D-aspartate (NMDA) antagonist, MK-801 (0.5 to 2.0 mM), inhibits rabies virus infection in rat primary cortical neurons, whereas the competitive NMDA antagonist AP5 has no effect. The results suggest that MK-801-mediated inhibition of rabies virus replication, although selective, is not operating through the high-affinity binding site mechanism.
Rabies virus is highly neurotropic as observed by electron microscopy (14) and in vitro studies of primary neuronal cultures (13, 22) . The virus-induced histopathological lesions are not a satisfactory explanation for the lethality of rabies virus (17) , raising the possibility that virus-mediated neuronal dysfunction is involved. Previous studies examining the binding of radiolabeled antagonists to neurotransmitter receptors (11, 12) and recording the electrical activity of chronically implanted mice (8) have shown that certain brain functions are modified during experimental rabies virus infection. Furthermore, early neuronal functional alterations can occur before the onset of clinical symptoms (8; also unpublished data). These studies point to virus-induced functional alterations as possible mechanisms of rabies pathogenesis causing the fatal issue of the disease by a series of as yet undefined events.
Several noninfectious pathological situations affecting neurons in the brain were shown to be a result of the action of excitatory amino acids such as L-glutamate and L-aspartate (20) . Indeed, glutamate-induced neurotoxicity has been reported to be a factor involved in the development of Huntington's chorea (16), Alzheimer's disease (9) , and Parkinson's disease (10) . It is now recognized that the neurotoxicity of excitatory amino acids is related to N-methyl-Daspartate (NMDA) receptor activation (5) . The ability of noncompetitive NMDA antagonists to confer a protective effect against various pathological events in neurons is now firmly established (2, 4, 18) . Among these drugs, the neuroprotective effects of the NMDA antagonist MK-801 have been successfully tested against glutamate neurotoxicity (6, 18, 19) and ischemia (7, 15) . Herein we report the antiviral effects of MK-801 during rabies virus infection of rat cortical neurons.
Cortical neurons were prepared from 14-day-old rat embryos. The cortices were mechanically dissociated and seeded into 35-mm-diameter polyornithine (2 jig/ml) (Sigma Chemicals, St. Louis, Mo.)-coated petri dishes (Falcon; Becton Dickinson, Grenoble, France) containing F10 medium (Boehringer, Mannheim, Federal Republic of Germany) supplemented with fetal calf serum (7.5%), horse serum (7.5%), and nerve growth factor (10 ng/ml) (Collaborative Research Inc., Lexington, Mass.). After 7 days of * Corresponding author. culture in a humid (water-saturated) CO2 incubator, the neurons were observed as refringent cells extending neurites at the surface of a monolayer of nonneuronal cells consisting mainly of glial cells.
A fixed rabies challenge virus strain (CVS) adapted to BHK (baby hamster kidney) cells was prepared as previously described (22) . Cortical neurons were infected with virus (106 PFU/ml) for 1 h at 37°C, the viral inoculum was then removed by repeated washings, and prewarmed medium was added. In the MK-801 experiments, the drug was added to the medium after virus inoculation and was present in the culture supernatant for the duration of each experiment. Samples were taken from the culture supernatant at daily intervals for assay by plaque titration with CER cells.
MK-801(+), MK-801(-), and AP5 were purchased from Research Biochemicals Inc. (Natick, Mass.); MK-801 was also a gift from Merck Sharp and Dohme (Rahway, N.J.). The antagonists were shown in preliminary experiments to be nontoxic to the cultured neurons at the selected concentrations. To eliminate the hypothesis that MK-801 could have been directly virucidal, samples of the rabies virus suspension were incubated with 1 mM MK-801 at 37°C in dishes in the absence of cells. Virus titers from the suspensions at 24 and 48 h showed no significant virucidal effect at 24 h, whereas less than a 10-fold decrease is observed after 48 h of incubation.
The dose-dependent effect of MK-801 was evaluated in neuronal cultures after virus inoculation. The virus yields after 3 days of infection showed a dose-related inhibitory effect of MK-801, active in the range of 0.5 to 2 mM (Fig. 1) . Kinetic studies after infection of neurons showed that 1 mM MK-801 inhibits the production of virus with an approximate 1,000-fold decrease for up to 4 days (Fig. 2) . In a similar experiment with NMDA competitive antagonist AP5, no difference in the kinetics of virus production between treated and control cultures was observed (Fig. 3) . To assess the specificity of MK-801 antiviral activity, its inactive isomer, MK-801(-), was used in parallel with the active form, MK-801(+). No significant difference in virus titer was found for the two drugs, which inhibited virus infection to the same extent.
The present studies show an antiviral effect of MK-801 in rat cortical neurons infected with the neurotropic rabies virus which is not the result of a virucidal effect of the drug. The antiviral action of MK-801 seems to be selective, since replication of herpes simplex virus, vesicular stomatitis virus, poliovirus type 1, and human immunodeficiency virus was not inhibited by the drug (unpublished observations). To our knowledge, it is the first such report of an antiviral activity for a neurotransmitter antagonist. The antiviral mechanism of action of MK-801 is not known, but additional data indicate that other noncompetitive NMDA antagonists, such as ketamine and phencyclidine derivates, also have antiviral properties (unpublished data). The observation that competitive antagonist AP5 did not modify virus production indicates that the antiviral action is restricted to noncompetitive antagonists, suggesting that the site of the antiviral effect is not located at the neurotransmitter binding site. In the present studies, the antiviral activity of MK-801 is efficient only in the millimolar range, in contrast to the 10 (3, 23) . This observation together with other data suggest that the antiviral activity is probably not operating through a high-affinity NMDA-binding mechanism. In fact, the noncompetitive NMDA antagonists also affect the functions of other neurotransmitters besides those related to excitatory amino acids (1, 21, 24) , but involvement of mechanisms other than neurotransmitter systems cannot be excluded. Further studies are needed to elucidate the antiviral mechanism of action of MK-801 by investigating other cellular function that might play a role in the neuronal regulation of rabies virus replication and by identifying the viral replication step inhibited by the drug. 
